Achille AOUBA
University Hospital, Caen
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Achille AOUBA as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:36 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT02902731 · Giant Cell Arteritis and Anakinra TrialUniversity Hospital, Caen · terminated · Giant Cell Arteritis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:36 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- 36 citationsRCR 0.9
- Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.PLoS One · 202217 citationsRCR 1.0
- Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.Leuk Res · 200912 citationsRCR 0.4
- Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis Res Ther · 20258 citationsRCR 2.3
- Efficacy, tolerance and acceptability of pulsed dye laser on facial and neckline telangiectasias in systemic scleroderma: a prospective open-label monocentric study in 21 patients.J Cosmet Laser Ther · 20233 citationsRCR 0.5
- Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system.Curr Med Res Opin · 20172 citationsRCR 0.1